Previous 10 | Next 10 |
The FDA has extended its action date to September 10 for its review of Xeris Pharmaceuticals' (NASDAQ: XERS ) marking application for Gvoke (ready-to-use glucagon injection) for the treatment of severe hypoglycemia (low blood sugar). More news on: Xeris Pharmaceuticals, Inc., Healthcare ...
CHICAGO, June 06, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that the U.S. Food a...
Gainers: La Jolla Pharmaceutical (NASDAQ: LJPC ) +87% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +74% . Ciena Corporation (NYSE: CIEN ) +24% . Cidara Therapeutics (NASDAQ: CDTX ) +21% . Dynatronics Corporation (NASDAQ: DYNT ) +16% . Stitch Fix (NASDAQ: SFIX ) +15% . Eloxx Phar...
Xeris Pharmaceuticals (NASDAQ: XERS ): Q1 GAAP EPS of -$1.07 misses by $0.26 . Revenue of $0.25M (-3.8% Y/Y) beats by $0.18M . Press Release More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ and Gvoke PFS ™ Dosed first patient in a Phase 2 study evaluating ready-to-use (RTU) glucagon in EIH Advancing diazepam to Phase 2 based on recently reported favorable Phase 1 results ...
Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and ...
Favorable pharmacokinetic, safety, and tolerability results support continued development of Xeris’ diazepam Phase 2 study to be initiated in 2H2019 CHICAGO, May 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company lever...
CHICAGO, April 26, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on April 24, 2019, ...
"Freedom began on the day the first sheep wandered away from the herd ." - Marty Rubin Today, we look at a small healthcare concern with a familiar business model. The company recently addressed its funding needs, has a potential product approval on the horizon, and is selling near all-ti...
CHICAGO, March 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on March 27, 2019, ...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...